The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection

Hussam Abuissa, James O'Keefe

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.

Original languageEnglish
Pages (from-to)1157-1166
Number of pages10
JournalDiabetes, Obesity and Metabolism
Volume10
Issue number12
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Renin-Angiotensin System
Type 2 Diabetes Mellitus
Kidney
Therapeutics
Angiotensin Receptor Antagonists
Incidence
Angiotensin-Converting Enzyme Inhibitors
MEDLINE
Cardiovascular Diseases
Blood Pressure
Hypertension

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. / Abuissa, Hussam; O'Keefe, James.

In: Diabetes, Obesity and Metabolism, Vol. 10, No. 12, 2008, p. 1157-1166.

Research output: Contribution to journalReview article

@article{945083bf17414209aefda9a907d2df1c,
title = "The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection",
abstract = "Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.",
author = "Hussam Abuissa and James O'Keefe",
year = "2008",
doi = "10.1111/j.1463-1326.2008.00898.x",
language = "English",
volume = "10",
pages = "1157--1166",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection

AU - Abuissa, Hussam

AU - O'Keefe, James

PY - 2008

Y1 - 2008

N2 - Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.

AB - Hypertension increases the risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. In addition to lowering blood pressure, blockade of the renin-angiotensin-aldosterone system (RAAS) reduces the risk of new-onset T2DM and offers renal protection. Using a MEDLINE search, we identified multiple trials that reported the incidence of T2DM in patients taking inhibitors of RAAS. In this review, we will discuss the RAAS as a potential target in diabetes prevention and the mechanisms through which inhibitors of this system achieve such an important effect. We will also shed light on the beneficial cardiovascular and renal effects of RAAS blockade. Although multiple studies have demonstrated that inhibitors of RAAS, especially angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, can reduce the incidence of T2DM, randomized controlled studies are still needed to further elucidate their exact role in diabetes prevention.

UR - http://www.scopus.com/inward/record.url?scp=55549124195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549124195&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2008.00898.x

DO - 10.1111/j.1463-1326.2008.00898.x

M3 - Review article

VL - 10

SP - 1157

EP - 1166

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 12

ER -